Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fate Therapeutics Q1 2024 GAAP EPS $(0.47), Inline, Sales $1.925M Beat $1.114M Estimate

Author: Benzinga Newsdesk | May 09, 2024 04:05pm
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 147.37 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $1.925 million which beat the analyst consensus estimate of $1.114 million by 72.76 percent. This is a 96.74 percent decrease over sales of $58.980 million the same period last year.

Posted In: FATE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist